A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Completed · Phase 3 · Has a placebo group

Conditions studied: Arthritis, Rheumatoid

In brief

The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.

Key facts

Study ID

NCT02019472

Run by

Janssen Research & Development, LLC

People needed

559

Starts

2014-04-04

Expected to finish

2016-08-17

Last updated by the study team

2017-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening
• Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66 swollen joints, at screening and at baseline
• Have previous or current treatment with methotrexate (MTX) and are considered intolerant to MTX, and/or are considered inappropriate for treatment with MTX, (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or an inadequate responder to methotrexate
• Must not have received MTX or any other non-biologic DMARD including but not limited to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2 weeks prior to the first administration of the study agent
• C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at screening

You may not qualify if…

• Has Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
• Has ever received biologic therapy for RA, including but not limited to the following: TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept
• Has ever used tofacitinib therapy or any other JAK inhibitor
• Has received intra-articular, intramuscular, or IV corticosteroids for RA, including adrenocorticotrophic hormone during the 4 weeks prior to first study agent administration
• Has received leflunomide within 24 months before the first study agent administration and has not undergone a drug elimination procedure, unless the M1 metabolite is measured and is undetectable

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Arvin, California, United States
• Study site — El Cajon, California, United States
• Study site — Huntington Beach, California, United States
• Study site — Pleasanton, California, United States
• Study site — Thousand Oaks, California, United States
• Study site — Tustin, California, United States
• Study site — Whittier, California, United States
• Study site — Newark, Delaware, United States
• Study site — Aventura, Florida, United States
• Study site — Dunedin, Florida, United States
• Study site — Miami, Florida, United States
• Study site — New Port Richey, Florida, United States
• Study site — Palm Harbor, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Kansas City, Kansas, United States
• Study site — Elizabethtown, Kentucky, United States
• Study site — Paducah, Kentucky, United States
• Study site — Frederick, Maryland, United States
• Study site — Wheaton, Maryland, United States
• Study site — St Louis, Missouri, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Salisbury, North Carolina, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.